Polypill Strategy in Secondary Cardiovascular Prevention

• DOI: 10.1007/s11886-024-02046-1
• Publication Date: 2024-04-01T10:02:18Z
• Authors: Alan De la Rosa; Kedzie Arrington; Rohan Desai; Prakrati C. Acharya
• Keywords: Polypill; Mace; Secondary Prevention; Guideline

The polypill strategy, originally developed to improve medication adherence, has demonstrated efficacy in improving baseline systolic blood pressures and cholesterol levels in multiple clinical trials. However, the long-term clinical impact of improved major cardiovascular events (MACE) outcomes by the polypill remains uncertain.Recent trials with long-term follow-up, which included minority groups and people with low socioeconomic status, have shown non-inferiority with no difference in adverse effects rates for the secondary prevention of MACE. Although the polypill strategy was initially introduced to improve adherence to guideline-directed medical therapy (GDMT) for cardiovascular complications, the strategy has surpassed standard medical treatment for secondary prevention of MACE outcomes. Studies also showed improved medication compliance in underserved populations.